

- CURRICULUM VITAE -

Dott. Federico Ravaioli, M.D., Ph.D.

PERSONAL INFORMATION			
Full name	Federico Ravaioli	E-mails	f.ravaioli@unibo.it
Work Address	Via Massarenti, 9, 40138 Bologna, Italy	Date of birth	2 nd August 1991
Personal Address	Via Pellegrino Matteucci, 4, 40137 Bologna, Italy	Nationality	Italian
Telephone	+39 333 3176759	Medical register number	BO-17801
ORCID	0000-0002-1142-8585	Web of Science	
		ResearcherID:	A-9335-2019
EDUCATION AND ACADEMIC QUALIFICATIONS			
Alma Mater Studiorum – Università di Bologna, Bologna, Italia Postdoctoral Researcher in Hepatology - – Department of Medical and Surgical Sciences (DIMEC) Title: <i>"Risk factors for diagnosis and response to systemic therapies of hepatocellular carcinoma (HCC) in consideration of the new nomenclature of steatotic liver disease (MASLD) in patients with advanced chronic liver disease"</i>, Tutor: Prof. Fabio Piscaglia. 11/23 to date			
Italian National Academic Qualification (ASN) as Associate Professor in Internal Medicine (MED/09) Associate Professor in Gastroenterology (MED/12) 10/23 – 10/34			
- Alma Mater Studiorum – University of Bologna, Bologna, Italy Subject Expert and Teaching Assistant ("Cultore della Materia") in MED/09 "Internal Medicine" 03/23 to date - University of Modena & Reggio Emilia, Modena, Italy Subject Expert and Teaching Assistant ("Cultore della Materia") in MED/12 "Gastroenterology & Hepatology"			
- Alma Mater Studiorum – University of Bologna, Bologna, Italy Medical Specialist in Clinical Nutrition & Metabolism (Gastroenterology & Internal Medicine training equivalence) Tutor: Prof. Maria Letizia Petroni; Final grade: 110/110 magna cum laude 11/19 – 10/23 - Newcastle University, Newcastle upon Tyne, UK Visiting Research Associate The Liver Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK Research Passport Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle University, Newcastle upon Tyne, UK 09/18 - 09/19 - Alma Mater Studiorum – University of Bologna, Bologna, Italy Doctor of Philosophy (PhD) in Gastroenterology (MED/12) Thesis: <i>"ELASTOVOD PROJECT: Prospective studies to evaluate the preclinical diagnostic potential of hepatic ultrasound-based elastography measurement for predicting the development of Sinusoidal Obstruction Syndrome (SOS/VOD) and hepatic complications in patients undergoing hematopoietic stem cell transplantation (HSCT)"</i> Coordinator: Prof. Fabio Piscaglia; Tutor: Prof. Davide Festi; Final grade: Excellent – cum laude 09/16 – 10/19 - Membership of Italian Physicians Registry, Bologna, Italy 2017 - Alma Mater Studiorum – University of Bologna, Bologna, Italy Doctor of Medicine (MD) Thesis: <i>"Clinical meaning of liver and spleen measurement by transient elastography (TE) in compensated advanced chronic liver disease (cACLD) HCV-patients treated with direct-acting antivirals (DAA)"</i> 10/10 – 06/16			

Tutor: Prof. Davide Festi; Final grade: 110/110 magna cum laude

- Liceo Scientifico "Torricelli-Ballardini", Faenza, Italy

2005 - 2010

PROFESSIONAL & RESEARCH ACCREDITATION

- "Good Clinical Practice (GCP) Certified, 2018 (revalidated 2022)
- Basis Life Support Defibrillation - Italian Resuscitation Council (IRC), 2016 (revalidated 2019, 2022)
- Advance Life Support (ALS) - Italian Resuscitation Council (IRC), Ospedale Maggiore di Bologna 2023

PROFESSIONAL EXPERIENCE

Current Position

11/2023 – to date

Department of Digestive, Liver, and Endocrine-Metabolic Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, (IT)

Consultant in Hepatology, Internal Medicine and Clinical Nutrition, Division of Internal Medicine, Hepatobiliary and Immunoallergic Diseases (Prof. Fabio Piscaglia)

Past Positions

02/2022 to 11/2023

University Hospital of Modena - University of Modena & Reggio Emilia, Modena, Italy

Consultant in Hepatology and Gastroenterology, Gastroenterology Unit, Department of Medical Specialities (Prof. Antonio Colecchia)

11/2019 to 11/2023

Department of Digestive, Liver, and Endocrine-Metabolic Diseases, IRCCS St. Orsola Hospital, Bologna, Italy

Clinical Fellow in Clinical Nutrition and Metabolism, Clinical Nutrition, Metabolism Unit and Center for Chronic Intestinal Failure (Prof. Loris Pironi).

Post-Graduate Clinical Training

- IRCCS St. Orsola University Hospital, University of Bologna, Italy
Clinical Nutrition, Metabolism Unit and Center for Chronic Intestinal Failure – (Prof. Loris Pironi)
Gastroenterology & Liver Unit – (Prof. Davide Festi, Prof. Franco Bazzoli, Prof. Giuseppe Mazzella)
Internal Medicine Unit (Prof. Fabio Piscaglia)
- Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle University, Newcastle upon Tyne, UK – Prof. Quentin Anstee
- Azienda Unità Sanitaria Locale della Romagna, Ravenna, Italy
Vaccinator Doctor – SarsCoV2 COVID-19 pandemic (2020-2021)
Tourist Medical Doctor (2017 & 2018)

Pre-Graduate Clinical Training

- St. Orsola University Hospital, University of Bologna, Italy
Gastroenterology & Liver Unit – (Prof. Davide Festi, Prof. Franco Bazzoli, Prof. Giuseppe Mazzella)
Internal Medicine Unit IBD Unit (Prof. Massimo Campieri)
Internal Medicine Unit (Prof. Luigi Bolondi)
- School of Medicine and Surgeries – University of Nairobi, Kenya
International Federation of Medical Students Association (IFMSA) clerkship in Internal medicine, general surgery and gastroenterology (07/2015-08/2015)

ACCADEMIC, SOCIAL & POLITICAL ACTIVITIES

- Italian Association of Dietetics and Clinical Nutrition (ADI) (2023 – to date)
Emilia-Romagna Section Regional Governing Board Member
- Osservatorio Regionale per la Formazione Medico Specialistica – Regione Emilia-Romagna (12/2020 to date)
Medical Resident Representative for the University of Bologna (12/2020 to 11/2023)

- Dipartimento Medico-Chirurgico (DAI) delle Malattie digestive, Epatiche ed Endocrino Metaboliche, IRCCS St. Orsola University Hospital, University of Bologna, Italy
Medical Resident Representative (12/2021 to 11/2023)
- Dipartimento di Scienze Mediche e Chirurgiche (DIMEC), University of Bologna, Bologna, Italy
PhD Students Representative (2016-2019)
- Segretariato Italiano Studenti in Medicina (Italian Medical Students' Association - SISM) – Sede Locale di Bologna, University of Bologna, Bologna, Italy
Administrator of Local Committee of SISM (2013-2016)

RESEARCH PRIZES, AWARDS & BURSARIES

- | | |
|---|------------------------------|
| • EBMT Best Young Poster Award (€500) - presented at the 49th Annual Meeting of the EBMT (April 2023) | 2023 |
| • Prize for "Premio Fidanza" Award (€1.000) – 13 th International Mediterranean Meeting | 2022 |
| • Prize for Best Poster presented at Annual congress of "Associazione Italiana Studio Fegato (AISF)" | 2022 |
| • Prize for Best Research Presentation at "Congresso Nazionale delle Malattie Digestive (FISMAD)" | 2018 |
| • Marco Polo Program Fellowship, University of Bologna (€14.000) | 2018 |
| • European Association for the Study of the Liver (EASL) – Young Investigator Bursaries & Travel Grants for International Liver Congress and Monothematic EASL Congress | 2016, 17, 18, 19, 20, 22, 23 |
| • United European Gastroenterology (UEG) – Travel Grant | 2016 |

CONGRESS SPEECH & LECTURES

- | | |
|---|------------------------------|
| • EASL-AASLD MASTERCLASS 2023 | 30/11 – 02/12/2023 |
| • Lecture - "Bookmarks 2022: Novità dell'anno in epatologia XVII edizione", Bologna, Italy | 11/2022 |
| • Lecture – "Diagnosi precoce della NAFLD/MASLD nel Diabete Mellito e nell'Obesità: benefici di un intervento tempestivo", Bologna, Italy | 20/10/2022 |
| • Oral Presentation at "International Liver Congress 2023 of European Association for the Study of the Liver (EASL)", Vienna, Austria | 06/2023 |
| • Lecture - "Bookmarks 2022: Novità dell'anno in epatologia XVII edizione", Bologna, Italy | 11/2022 |
| • Lecture - "Meeting della Gastroenterologia di Modena", Modena, Italy | 11/2022 |
| • Lecture - "Da qui all'Obesità", Parma, Italy | 10/2022 |
| • Lecture - "La malattia veno-occlusiva epatica, focus sulle tecniche di imaging", Modena, Italy | 06/2022 & 11/2022 |
| • Oral Presentation at "13 th International Mediterranean Meeting", Venice, Italy | 05/2022 |
| • Lecture - INVESTIGATOR MEETING "Studio multicentrico italiano ElastoVOD: aggiornamento e confronto fra i Centri Sperimentatori", Bologna, Italy | 12/2018 – 2019 – 2020 – 2021 |
| • Lecture - Attraversare confini in Gastroenterologia: Ipertensione portale non cirrotica, Bologna, Italy | 12/2019 |
| • Oral Presentation at "44th Annual Meeting of European Society for Blood and Bone Marrow Transplantation (EBMT)", Lisbon, Portugal | 05/2018 |
| • Oral Presentation at "International Liver Congress 2018 of European Association for the Study of the Liver (EASL)", Paris, France | 04/2018 |
| • Lecture - Imaging Training Course VOD, Bologna, Italy | 03/2018 |
| • Oral Presentation at "Congresso Nazionale delle Malattie Digestive 2018 (FISMAD)", Rome, Italy | 03/2018 |

ESTEEM INDICATORS & PROFESSIONAL ACTIVITIES

Fellowships & Memberships of Medical Societies

- Società Italiana di Medicina Interna – 2023 to date
- Società Italiana di Gastroenterologia – 2024 to date
- Associazione Italiana di Dietetica e Nutrizione Clinica (ADI) – 2021 to date
- European Association for the Study of the Liver (EASL) – 2016 to date
- Associazione Italiana Studio Fegato (AISF) – 2016 to date
- United European Gastroenterology (UEG) – 2016-2017

Journal Editorial Board Membership

- Heliyon – Associate Editor “Clinical Research – Hepatology & Gastroenterology” CiteScore 5.6; IF 4)
- Canadian Journal of Gastroenterology & Hepatology – Section Editor “Hepatology” (CiteScore 4; IF 2.7)
- Frontiers in Oncology – Associate Editor “Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers (CiteScore 5.2; IF 4.7)
- Nutrients Guest Editor of Special Issue “Nutritional Challenge in Advanced Chronic Liver Disease and Complications Related to Portal Hypertension” (CiteScore 9; IF 5.9)
- Hepatoma Research – Editorial Board Member (Citescore 3.1)
- Artificial Intelligence in Gastroenterology – Editorial Board Member
- Portal Hypertension & Cirrhosis (PH&C) – Editorial Board Member

Peer-Review (103 verified WOS)

- | | |
|--|---|
| • European Radiology (26) | • Frontiers in Oncology (2) |
| • Ultraschall in der Medizin - European Journal of Ultrasound (11) | • Expert Review in Gastroenterology & Hepatology (2) |
| • Alimentary Pharmacology & Therapeutics (6) | • World Journal of Hepatology (2) |
| • Digestive and Liver Disease (5) | • Nutrition (2) |
| • JHEP Reports (4) | • Journal of Gastroenterology and Hepatology (2) |
| • Scientific Reports (4) | • Portal Hypertension & Cirrhosis (2) |
| • Clinical Gastroenterology and Hepatology (3) | • Biomedicines (1) |
| • Canadian Journal of Gastroenterology & Hepatology (3) | • Biomolecules (1) |
| • Cancers (3) | • Current Medical Research and Opinion (1) |
| • Liver International (3) | • EClinical Medicine (1) |
| • Therapeutic Advances in Hematology (3) | • European Journal of Gastroenterology & Hepatology (1) |
| • BMC Gastroenterology (2) | • Frontiers in Endocrinology (1) |
| • Artificial Intelligence in Gastroenterology (2) | • Gastroenterology Report (1) |
| • Clinical Nutrition ESPEN (2) | • Journal of Gastrointestinal and Liver Diseases (1) |
| • Clinics and Research in Hepatology and Gastroenterology (2) | • Nutrition Metabolism and Cardiovascular Diseases (1) |
| • Communications Medicine (2) | • Pharmaceuticals (1) |
| | • Plos One (1) |

CLINICAL TRIAL ACTIVITY

Participation in International Research study group:

- BAVENO VII-NAFLD validation study group (Italy, Spain, Hong Kong, Canada, Switzerland)
- VEB6 (validation of expanded Baveno VI criteria) study group (France, Italy, Romania, Switzerland, UK, Hong Kong, Canada)
- VALDIG (Vascular Liver Disease Group)
- European Reference Network for (ERN) Rare Liver
- Chinese Portal Hypertension Alliance (CHESS)

Study Coordinator & Protocol author:

- ELASTOVOD ITALIAN MULTICENTRIC STUDY (NCT03426358)
- ELASTOSURGERY Multicentre International Study
- ELASTOMETAVOD Study
- KETONASH Study

Disease registry member:

- BOlogna Group for Autoimmune Liver Disease (BOGALD)
- BOlogna LIVER vascular Studies (BO-LIVES)
- Italian Liver Cancer (ITA.LI.CA) Study Group

Research study physician:

- ASCEND-NASH (HEPA-CRV431-207): Phase 2B RCT (Rencofilstat, also known as CRV431), Sponsor: Hepion Pharmaceuticals, Inc., 2022 to date
- ESSENCE: Phase 3 RCT (IMP: Semaglutide), Sponsor: Novo Nordisk, 2022 to date
- RESOLVE-IT: Phase 3 RCT (IMP: Elafibranor), Sponsor: Genfit, 2016 - 2021
- REGENERATE (747-303): Phase 3 RCT (IMP: Obeticholic acid), Sponsor: Intercept, 2016-2021.

SCIENTIFIC PUBLICATION (09/2016 -02/2024)

Overall Summary of Publications (Scopus)				
Peer-Reviewed Research Publications	First, Last & Corresponding author, %	Citation Impact	Top 25% Journals	International collaboration
140 (WOS)	30 (33.7%)	24.1	66.7%	25.7%
<i>Google Scholar</i> : h-index 26, i10-index 48, total citations: 2401				
<i>Scopus</i> : h-index 24, total citations: 1833				
<i>Web of Sciences (WOS)</i> : h-index 22, total citations: 1625				

PUBLISHED PEER-REVIEWED JOURNAL ARTICLES:**NOTE:**

*The authors contributed to this manuscript equally and co-shared the first authorship

§ Corresponding/ Last author

- ♦ Dalbeni A, Mantovani A, Lombardi R, **Ravaioli F**[§]. Reply: Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Hepatology. 2023 doi: [10.1097/HEP.0000000000000721](https://doi.org/10.1097/HEP.0000000000000721).
- ♦ Dalbeni A, Lombardi R, Henrique M, Zoncapè M, Pennisi G, Petta S, Tateishi R, Keklikkiran C, Colecchia A, Sacerdoti D, Mantovani A, **Ravaioli F**[§]. Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Hepatology. 2023 doi: [10.1097/HEP.0000000000000694](https://doi.org/10.1097/HEP.0000000000000694).
- ♦ Pelizzaro F, Trevisani F, Simeon V, ...**Ravaioli F**, ... et al. Italian Liver Cancer (ITA.LI.CA) Study Group. Italian Liver Cancer (ITA.LI.CA) group. Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection. Liver Int. 2023 doi: [10.1111/liv.15719](https://doi.org/10.1111/liv.15719).
- ♦ Dajti E*, **Ravaioli F***, Paiola G, Volpi S, Colecchia L, Ferrarese A, Alemanni LV, Cusumano C, Di Biase AR, Marasco G, Vestito A, Festi D, Rautou PE, Cipolli M, Colecchia A. The non-invasive evaluation of liver involvement in patients with cystic fibrosis: A prospective study. Liver Int. 2023 doi: [10.1111/liv.15748](https://doi.org/10.1111/liv.15748).

- ◆ Dajti E, **Ravaoli F**, Zyklus Romans, ... et al. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis. The Lancet Gastroenterology and Hepatology 2023. [10.1016/S2468-1253\(23\)00150-4](#)
- ◆ Pennisi G, Enea M, ... **Ravaoli F**, ... et al. Oesophageal varices predict complications in compensated advanced non-alcoholic fatty liver disease. JHEP Reports 2023 [10.1016/j.jhepr.2023.100809](#)
- ◆ Leoni L, Valoriani F, ... **Ravaoli F** et al. Unlocking the Power of Late-Evening Snacks: Practical Ready-to-Prescribe Chart Menu for Patients with Cirrhosis. Nutrients 2023 [10.3390/nu15153471](#)
- ◆ Reggidori N, Bucci L, ... **Ravaoli F**, ... et al. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs JHEP Reports 2023 [10.1016/j.jhepr.2023.100784](#)
- ◆ Piscaglia F, La Mura V & **Ravaoli F**. A pragmatic strategy for the screening and treatment of portal hypertension in patients needing systemic treatment for advanced hepatocellular carcinoma. Digestive and Liver Disease 2023 [10.1016/j.dld.2023.05.017](#)
- ◆ **Ravaoli F**, De Maria N, Di Marco L et al. From Listing to Recovery: A Review of Nutritional Status Assessment and Management in Liver Transplant Patients Nutrients 2023 [10.3390/nu15122778](#)
- ◆ **Ravaoli F***, Dajti E*, Mantovani A et al. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis. Gut. 2023 [10.1136/gutjnl-2022-328689](#)
- ◆ Musio A, Perazza F, ... **Ravaoli F** et al. Osteosarcopenia in NAFLD/MAFLD: An Underappreciated Clinical Problem in Chronic Liver Disease. Int J Mol Sci. 2023 [10.3390/ijms24087517](#).
- ◆ **Ravaoli F**, Berger A, Farcau O, et al. Individual and population screening of varices needing treatment by a simple, safe and accurate test. Clin Res Hepatol Gastroenterol. 2023 [10.1016/j.clinre.2023.102123](#)
- ◆ Benevento F, Pecorelli A, ..., **Ravaoli F**, ... et al. Presence of Hepatocellular Carcinoma Does Not Affect Course and Response to Anticoagulation of Bland Portal Vein Thrombosis in Cirrhotic Patients. J Hepatocell Carcinoma. 2023 [10.2147/JHC.S390777](#)
- ◆ Dajti E, Renzulli M, **Ravaoli F**, ... et al. The interplay between sarcopenia and portal hypertension predicts ascites and mortality in cirrhosis. Digestive and Liver Disease. 2023 [10.1016/j.dld.2022.11.011](#)
- ◆ Casciola R, Leoni L, ... **Ravaoli F** et al. Creatine Supplementation to Improve Sarcopenia in Chronic Liver Disease: Facts and Perspectives. Nutrients 2023 [10.3390/nu15040863](#)
- ◆ Piscaglia F and **Ravaoli F**, Gaining knowledge for the choice and use of systemic therapies in the treatment of hepatocellular carcinoma also requires real life and investigators conducted observational studies, Digestive and Liver Disease. 2022. [10.1016/j.dld.2022.08.032](#)
- ◆ Stefanini B, Terzi E, Giamperoli A, ..., **Ravaoli F**, Piscaglia F et al., Letter to the editor on the article "Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Hepatocellular Carcinoma: Diagnostic Performance and Interobserver Agreement" by Zhou and collaborators. 2022 Ultraschall in der Medizin - European Journal of Ultrasound. [10.1055/a-1978-5690](#)
- ◆ Stefanini B, Bucci L, Santi V, ... **Ravaoli F**, ... et al. Italian Liver Cancer (ITA.LI.CA) Study Group. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors. Digestive and Liver Disease. 2022. [10.1016/j.dld.2022.07.003](#)
- ◆ Lasagni S, Leonardi F, Pivetti A, ... **Ravaoli F**, ... Villa E. et al. Endothelial angiopoietin-2 overexpression in explanted livers identifies subjects at higher risk of recurrence of hepatocellular carcinoma after liver transplantation. Frontiers in Oncology. 2022. [10.3389/fonc.2022.960808](#)

- ◆ Giannini EG, Pieri G, Labanca S, ... **Ravaoli F**, ... et al. Italian Liver Cancer (ITA.LI.CA) Study Group. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma. Digestive and Liver Disease. 2022. [10.1016/j.dld.2022.03.002](https://doi.org/10.1016/j.dld.2022.03.002)
- ◆ **Ravaoli F**, Pivetti A, Di Marco L et al. Role of Vitamin D in Liver Disease and Complications of Advanced Chronic Liver Disease. 2022. IJMS [10.3390/ijms23169016](https://doi.org/10.3390/ijms23169016)
- ◆ Dajti E*, **Ravaoli F***, Marasco G, et al. A combined Baveno VII and spleen stiffness algorithm to improve the non-invasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease. 2022 Am J Gastroenterol. [10.14309/ajg.0000000000001887](https://doi.org/10.14309/ajg.0000000000001887)
- ◆ Cales P, **Ravaoli F**, Berger A, et al. Comparison of screening strategies with two new tests to score and diagnose varices needing treatment. 2022. Clinics and Research in Hepatology and Gastroenterology [10.1016/j.clinre.2022.101925](https://doi.org/10.1016/j.clinre.2022.101925)
- ◆ Caretto A, Pintus S, Petroni ML, ... **Ravaoli F**, ... et al. Determinants of weight, psychological status, food contemplation and lifestyle changes in patients with obesity during the COVID-19 lockdown: a nationwide survey using multiple correspondence analysis. 2022. Int J Obes. [10.1038/s41366-022-01100-8](https://doi.org/10.1038/s41366-022-01100-8)
- ◆ Pelizzaro D, Peresico G, D'Elia M, ... **Ravaoli F**, ... et al. Italian Liver Cancer (ITA.LI.CA) Study Group. Surveillance for hepatocellular carcinoma with a 3-months interval in "extremely high-risk" patients does not further improve survival. 2022. Digestive and Liver Disease [10.1016/j.dld.2021.08.025](https://doi.org/10.1016/j.dld.2021.08.025)
- ◆ Dajti E*, **Ravaoli F***, Colecchia A, et al. Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation After Direct-Acting Antivirals in HCV Cirrhotic Patients. 2022 Ultrascall in der Medizin - European Journal of Ultrasound. [10.1055/a-1205-0367](https://doi.org/10.1055/a-1205-0367)
- ◆ Stefanini B, Bucci L, Santi V, ... **Ravaoli F**, ... et al. Italian Liver Cancer (ITA.LI.CA) Study Group. Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors. 2022. Digestive and Liver Disease. [10.1016/j.dld.2022.07.003](https://doi.org/10.1016/j.dld.2022.07.003)
- ◆ Marasco G, Dajti E, Serenari M, ... **Ravaoli F**, ... et al. Sarcopenia Predicts Major Complications after Resection for Primary Hepatocellular Carcinoma in Compensated Cirrhosis. 2022. Cancers [10.3390/cancers14081935](https://doi.org/10.3390/cancers14081935)
- ◆ **Ravaoli F**, Marconi G, Martinelli G, et al. Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia. 2022. Cancer Medicine. [10.1002/cam4.4390](https://doi.org/10.1002/cam4.4390)
- ◆ Renzulli M, Dajti E, Ierardi AM, ... **Ravaoli F**, ... et al. Validation of a standardized CT protocol for the evaluation of varices and porto-systemic shunts in cirrhotic patients. 2022 European Journal of Radiology. [10.1016/j.ejrad.2021.110010](https://doi.org/10.1016/j.ejrad.2021.110010)
- ◆ Di Biase AR, Marasco G, **Ravaoli F**, et al. Clinical Presentation of Celiac Disease and Diagnosis Accuracy in a Single-Center European Pediatric Cohort over 10 Years. 2021. Nutrients. [10.3390/nu13114131](https://doi.org/10.3390/nu13114131)
- ◆ Cucchetti A, Gramenzi A, Johnson P, ... **Ravaoli F**, ... et al. Italian Liver Cancer (ITA.LI.CA) Study Group. Material deprivation affects the management and clinical outcome of hepatocellular carcinoma in a high-resource environment. 2021. European Journal of Cancer. [10.1016/j.ejca.2021.09.018](https://doi.org/10.1016/j.ejca.2021.09.018)
- ◆ Ferrarese A, Passigato N, Cusumano C, ... **Ravaoli F**, ... et al. Antibiotic prophylaxis in patients with cirrhosis: Current evidence for clinical practice. 2021. World Journal of Hepatology. [10.4254/wjh.v13.i8.840](https://doi.org/10.4254/wjh.v13.i8.840)

- ◆ Petroni ML, Brodosi L, Marchignoli F, ... **Ravaoli F**, et al. Nutrition in Patients with Type 2 Diabetes: Present Knowledge and Remaining Challenges. 2021. *Nutrients*. [10.3390/nu13082748](https://doi.org/10.3390/nu13082748)
- ◆ Cucchetti A, Giannini EG; Mosconi C, ... **Ravaoli F**, ... et al. Italian Liver Cancer (ITA.LI.CA) Study Group. Recalibrating survival prediction among patients receiving trans-arterial chemoembolization for hepatocellular carcinoma. 2021 *Liver Cancer International*. [10.1002/lci2.33](https://doi.org/10.1002/lci2.33)
- ◆ Marasco G, Colecchia A, Bacchi Reggiani ML, ... **Ravaoli F**, ... et al. Italian Liver Cancer (ITA.LI.CA) Study Group. Comparison of prognostic models in advanced hepatocellular carcinoma patients undergoing Sorafenib: A multicenter study. 2021. *Digestive and Liver Disease*. [10.1016/j.dld.2020.12.001](https://doi.org/10.1016/j.dld.2020.12.001)
- ◆ Guarino M, Cucchetti A, Pontillo G, ... **Ravaoli F**, ... et al. Italian Liver Cancer (ITA.LI.CA) Study Group. Pattern of macrovascular invasion in hepatocellular carcinoma. 2021, *Eur. J. Clin. Invest.* [10.1111/eci.13542](https://doi.org/10.1111/eci.13542)
- ◆ Dajti E, Marasco G, **Ravaoli F**, et al. The role of liver and spleen elastography in advanced chronic liver disease. 2021. *Minerva Gastroenterology*. [10.23736/S2724-5985.20.02793-2](https://doi.org/10.23736/S2724-5985.20.02793-2)
- ◆ Dajti E, Marasco G, **Ravaoli F**, et al. Risk of hepatocellular carcinoma after HCV eradication: Determining the role of portal hypertension by measuring spleen stiffness. 2021. *JHEP Reports* [10.1016/j.jhepr.2021.100289](https://doi.org/10.1016/j.jhepr.2021.100289)
- ◆ Marasco G, Poggioli F, Colecchia A, ... **Ravaoli F**, ... et al. Italian Liver Cancer (ITA.LI.CA) Study Group. A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study. 2021. *Cancers* [10.3390/cancers13112677](https://doi.org/10.3390/cancers13112677)
- ◆ Garuti F, Neri A, Avanzato F, ... **Ravaoli F**, ... et al. Italian Liver Cancer (ITA.LI.CA) Study Group. The changing scenario of hepatocellular carcinoma in Italy: an update. 2021 *Liver International*. [10.1111/liv.14735](https://doi.org/10.1111/liv.14735)
- ◆ Colosimo S*, **Ravaoli F***, Petroni ML, Brodosi L, Marchignoli F, Barbanti FA, Sasdelli AS, Marchesini G, Pironi L. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. *Liver Int.* 2021 Apr;41(4):731-742. doi: [10.1111/liv.14799](https://doi.org/10.1111/liv.14799).
- ◆ Dajti E, Renzulli M, Colecchia A, ..., **Ravaoli F**, ..., et al. Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients. *Dig Liver Dis.* 2021 Jan 4:S1590-8658(20)31195-6. doi: [10.1016/j.dld.2020.12.114](https://doi.org/10.1016/j.dld.2020.12.114).
- ◆ Govaere O, Cockell S, Tiniakos D, ..., **Ravaoli F**, ..., et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. *Sci Transl Med.* 2020 Dec 2;12(572):eaba4448. doi: [10.1126/scitranslmed.aba4448](https://doi.org/10.1126/scitranslmed.aba4448)
- ◆ Marasco G, Dajti E, **Ravaoli F**, ..., et al. Clinical impact of sarcopenia assessment in patients with liver cirrhosis. *Expert Rev Gastroenterol Hepatol.* 2021 Apr;15(4):377-388. doi: [10.1080/17474124.2021.1848542](https://doi.org/10.1080/17474124.2021.1848542). Epub 2020
- ◆ Pelizzaro F, Penzo B, Peserico G, ..., **Ravaoli F**, ..., Italian Liver Cancer (ITA.LI.CA) group. Monofocal hepatocellular carcinoma: How much does size matter? *Liver Int.* 2021 Feb;41(2):396-407. doi: [10.1111/liv.14718](https://doi.org/10.1111/liv.14718).
- ◆ Marasco G, Ricci C, Buttitta F, Dajti E, **Ravaoli F**, ..., et al. Is Ultrasound Elastography Useful in Predicting Clinically Relevant Pancreatic Fistula After Pancreatic Resection?: A Systematic Review and Meta-analysis. *Pancreas.* 2020 Nov/Dec;49(10):1342-1347. doi: [10.1097/MPA.0000000000001685](https://doi.org/10.1097/MPA.0000000000001685).
- ◆ Pironi L, Sasdelli AS, **Ravaoli F**, ..., et al. Malnutrition and nutritional therapy in patients with SARS-CoV-2 disease. *Clin Nutr.* 2021 Mar;40(3):1330-1337. doi:[10.1016/j.clnu.2020.08.021](https://doi.org/10.1016/j.clnu.2020.08.021).
- ◆ Dajti E, **Ravaoli F**, Festi D, Colecchia A. Clinical outcomes after treatment with direct-acting antivirals: not all concern hepatocellular carcinoma risk. *Hepatobiliary Surg Nutr.* 2020 Aug;9(4):505-507. doi: [10.21037/hbsn.2019.11.19](https://doi.org/10.21037/hbsn.2019.11.19).

- ◆ Serenari M, **Ravaoli F**, Cucchetti A, Kim SU, Cescon M. Reply to: "Response to A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma". J Hepatol. 2020 Nov;73(5):1270-1271. doi: 10.1016/j.jhep.2020.07.001.
- ◆ Marasco G, Serenari M, Renzulli M, ..., **Ravaoli F**, ... et al. Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments. J Gastroenterol. 2020 Oct;55(10):927-943. doi: 10.1007/s00535-020-01711-W.
- ◆ Serenari M, **Ravaoli F**, Cucchetti A, Kim SU, Cescon M. Reply to: "Liver stiffness: A novel predictor of postoperative complications in patients with hepatocellular carcinoma". J Hepatol. 2020 Oct;73(4):988-989. doi: 10.1016/j.jhep.2020.06.017
- ◆ Di Biase AR, Marasco G, **Ravaoli F**, et al. Gut microbiota signatures and clinical manifestations in celiac disease children at onset: a pilot study. J Gastroenterol Hepatol. 2021 Feb;36(2):446-454. doi: 10.1111/jgh.15183.
- ◆ Marasco G, Colecchia A, Silva G, ..., **Ravaoli F**, ... et al. Non-invasive tests for the prediction of primary hepatocellular carcinoma. World J Gastroenterol. 2020 Jun 28;26(24):3326-3343. doi: 10.3748/wjg.v26.i24.3326
- ◆ Chan SS, Colecchia A, Duarte RF, Bonifazi F, **Ravaoli F**, Bourhis JH. Imaging in Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome. Biol Blood Marrow Transplant. 2020 Oct;26(10):1770-1779. doi: 10.1016/j.bbmt.2020.06.016.
- ◆ Berger A*, **Ravaoli F***, Farcau O, et al. Including Ratio of Platelets to Liver Stiffness Improves Accuracy of Screening for Esophageal Varices That Require Treatment. Clin Gastroenterol Hepatol. 2021 Apr;19(4):777-787.e17. doi: 10.1016/j.cgh.2020.06.022.
- ◆ Marasco G, Dajti E, **Ravaoli F**, et al. Spleen stiffness measurement for assessing the response to β -blockers therapy for high-risk esophageal varices patients. Hepatol Int. 2020 Sep;14(5):850-857. doi:10.1007/s12072-020-10062-w.
- ◆ Serenari M, Han KH, **Ravaoli F**, et al. A nomogram based on liver stiffness predicts postoperative complications in patients with hepatocellular carcinoma. J Hepatol. 2020 Oct;73(4):855-862. doi: 10.1016/j.jhep.2020.04.032.
- ◆ Bonifazi F, Barbato F, **Ravaoli F**, et al. Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2020 Apr 3;11:489. doi: 10.3389/fimmu.2020.00489.
- ◆ Marasco G, Ricci C, Grasso V, ..., **Ravaoli F**, ... et al. Pancreatic ultrasound elastography is not useful to predict the risk of pancreatic fistulas after pancreatic resection. Updates Surg. 2020 Dec;72(4):1081-1087. doi: 10.1007/s13304-020-00748-z.
- ◆ Simili A, Mazzella G, **Ravaoli F**[§], et al. Interleukin 28 Polymorphisms and Hepatocellular Carcinoma Development after Direct Acting Antiviral Therapy for Chronic Hepatitis C. J Gastrointest Liver Dis. 2019;28(4):449-456. doi:10.15403/jgld-309
- ◆ Mantovani A, Turino T, Lando MG, ..., **Ravaoli F**, ... et al. Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes Diabetes Metab. 2020 Sep;46(4):296-303. doi:10.1016/j.diabet.2019.11.004.
- ◆ Stefanescu H, Marasco G, Calès P, ..., **Ravaoli F**, ..., et al. A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices. Liver Int. 2020 Jan;40(1):175-185. doi: 10.1111/liv.14228.
- ◆ **Ravaoli F**, Colecchia A. Sound Conclusions: How Splenic Elastography May Decrease the Need for Endoscopic Variceal Surveillance. Dig Dis Sci. 2019;64(9):2381-3. doi.org/10.1007/s10620-019-05731-2

- ◆ Zama D, Bossù G, **Ravaoli F**, Masetti R, Prete A, Festi D, et al. Longitudinal evaluation of liver stiffness in three pediatric patients with veno-occlusive disease. *Pediatr Transplant*. 2019 23(5):e13456. doi.org/10.1111/petr.13456
- ◆ **Ravaoli F**, Anstee QM. Editorial: collagen proportionate area as a prognostic indicator in NAFLD. *Aliment Pharmacol Ther*. 2019;49(11):1452–4. doi.org/10.1111/apt.15249
- ◆ **Ravaoli F**, Colecchia A, Alemanni LV, Vestito A, Dajti E, Marasco G, et al. Role of imaging techniques in liver veno-occlusive disease diagnosis: recent advances and literature review. *Expert Review of Gastroenterology and Hepatology*. 2019. 13:463–84 doi.org/10.1080/17474124.2019.1588111
- ◆ Dajti E*, **Ravaoli F***, Colecchia A, Marasco G, Vestito A, Festi D. Liver and Spleen Stiffness Measurements for Assessment of Portal Hypertension Severity in Patients with Budd Chiari Syndrome. *Can J Gastroenterol Hepatol*. 2019; 2019:1673197. doi.org/10.1155/2019/1673197
- ◆ Casadei Gardini A, Foschi FG, Conti F, Petracci E, Vukotic R, ..., **Ravaoli F**, et al. Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. *Dig Liver Dis*. 2019;51(5):681–8. doi.org/10.1016/j.dld.2018.09.016
- ◆ Marasco G, Colecchia A, Colli A, **Ravaoli F**, Casazza G, Bacchi Reggiani ML, et al. Reply to correspondence concerning: "Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection". *J Hepatol*. 2019;70(4):809–10. doi.org/10.1016/j.jhep.2018.12.025
- ◆ Colecchia A*, **Ravaoli F***, Sessa M, Alemanni VL, Dajti E, Marasco G, et al. Liver Stiffness Measurement Allows Early Diagnosis of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Adult Patients Who Undergo Hematopoietic Stem Cell Transplantation: Results from a Monocentric Prospective Study. *Biol Blood Marrow Transplant*. 2019;25(5):995–1003. doi.org/10.1016/j.bbmt.2019.01.019
- ◆ Dajti E*, **Ravaoli F***, Colecchia A, Marasco G, Calès P, Festi D. "Are the Expanded Baveno VI Criteria really safe to screen compensated cirrhotic patients for high-risk varices?", *Digestive and Liver Disease*. 2019. 51:456–7. doi.org/10.1016/j.dld.2018.12.01
- ◆ Marasco G, Colecchia A, Dajti E, **Ravaoli F**, Cucchetti A, Cescon M, et al. Prediction of posthepatectomy liver failure: Role of SSM and LSPS. *J Surg Oncol*. 2019;119(3):400–1. doi.org/10.1002/jso.25345
- ◆ Marasco G, Colecchia A, Colli A, **Ravaoli F**, Casazza G, Bacchi Reggiani ML, et al. Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection. *J Hepatol*. 2019; 70(3):440–8. doi.org/10.1016/j.jhep.2018.10.022.
- ◆ **Ravaoli F**, Colecchia A, Dajti E, Marasco G, Alemanni LV, Tamè M, et al. Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients. *World J Hepatol*. 2018;10(10):731–42. doi.org/10.4254/wjh.v10.i10.731
- ◆ Calès P, Buisson F, **Ravaoli F**, Berger A, Carboni C, Marasco G, et al. How to clarify the Baveno VI criteria for ruling out varices needing treatment by noninvasive tests. *Liver Int*. 2019;39(1):49–53. doi.org/10.1111/liv.13945
- ◆ **Ravaoli F**, Montagnani M, Lisotti A, Festi D, Mazzella G, Azzaroli F. Noninvasive assessment of portal hypertension in advanced chronic liver disease: An update, *Gastroenterology Research and Practice*. 2018. 2018:1–11. doi.org/10.1155/2018/4202091
- ◆ Festi D, Dajti E, **Ravaoli F**, Marasco G, Colecchia A. [Role and clinical meaning of non-invasive tests in the evaluation of portal hypertension in patients with advanced chronic liver disease]. *Recenti Prog Med*. 2018;109(12):574–84. doi.org/10.1701/3082.30742
- ◆ Casadei Gardini A, Conti F, Foschi FG, Brillanti S, Andreone P, Mazzella G, ..., **Ravaoli F** et al. Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-

related Cirrhosis Treated With Direct-acting Antivirals. *Gastroenterology*. 2018. 154:2281–2. doi.org/10.1053/j.gastro.2017

- ◆ Colecchia A*, **Ravaoli F***, Marasco G, Colli A, Dajti E, Di Biase AR, et al. A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease. *Journal of Hepatology*. 2018;69(2):308–17. doi.org/10.1016/j.jhep.2018.04.023.
- ◆ Morisco F., Camera S., Guarino M., ..., **Ravaoli F** et al. Laser ablation is superior to TACE in large-sized hepatocellular carcinoma: A pilot case-control study. *Oncotarget* 2018;9(25). doi.org/10.18632/oncotarget.24756.
- ◆ **Ravaoli F**, Conti F, Brilli S, Andreone P, Mazzella G, Buonfiglioli F, et al. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotic treated with direct acting antivirals. *Dig Liver Dis*. 2018;50(6):573–9. doi.org/10.1016/j.dld.2018.02.010.
- ◆ Piscaglia F, Salvatore V, Mulazzani L, Cantisani V, Colecchia A, Di Donato R, ..., **Ravaoli F** et al. Differences in liver stiffness values obtained with new ultrasound elastography machines and Fibroscan: A comparative study. *Dig Liver Dis*. 2017;49(7). doi.org/10.1016/j.dld.2017.03.001.
- ◆ Mulazzani L, Salvatore V, **Ravaoli F**, Allegretti G, Matassoni F, Granata R, et al. Point shear wave ultrasound elastography with Esaote compared to real-time 2D shear wave elastography with supersonic imagine for the quantification of liver stiffness. *J Ultrasound*. 2017;20(3). doi.org/10.1007/s40477-017-0260-7.
- ◆ Colecchia A, Marasco G, **Ravaoli F**, Kleinschmidt K, Masetti R, Prete A, et al. Usefulness of liver stiffness measurement in predicting hepatic veno-occlusive disease development in patients who undergo HSCT. Vol. 52, *Bone Marrow Transplantation*. 2017. p. 494–7. doi.org/10.1038/bmt.2016.320
- ◆ Festi D, **Ravaoli F**, Marasco G CA. Hepatic encephalopathy. *Recent Prog Med* 2016; July(07(7)):378–85. doi.org/10.1701/2318.24932
- ◆ Marasco G, Di Biase AR, Schiumerini R, Eusebi LH, Iughetti L, **Ravaoli F**, et al. Gut Microbiota and Celiac Disease. *Dig Dis Sci*. 2016;61(6):1461–72. doi.org/10.1007/s10620-015-4020-2.

CHAPTERS OF BOOKS

- ◆ Colecchia A., **Ravaoli F.**, Marasco G., et al. Spleen Stiffness by Ultrasound Elastography. *Diagnostic Methods for Cirrhosis and Portal Hypertension*. Cham: Springer International Publishing; 2018. p. 113–37
- ◆ Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management (Gastrointestinal & Liver Disease (Sleisenger/Fordtran) Italian Version; 2018.
- ◆ **Ravaoli F**, Dajti E, Alemanni VL, Colecchia A. Liver and Spleen Stiffness in Vascular Liver Disease. *Elastography of the Liver and Beyond*: Springer International Publishing; 2021. p. 235–255

CONGRESS ABSTRACT (UNTILL 2019)

- ◆ Azzaroli F, Simoni P, Arena R, Dajti E, **Ravaoli F**, et al. The role of bile acids profile and insulin resistance for the prediction of gallstone disease in a prospective cohort of blood donors «JOURNAL OF HEPATOLOGY», 2019, 70(1):e523
- ◆ Dajti E, **Ravaoli F**, Colecchia A, Marasco G et al. The role of liver and spleen stiffness measurement in predicting hepatic decompensation after HCV eradication with direct antiviral agents therapy «JOURNAL OF HEPATOLOGY», 2019, 70(1):e822-e82

- ◆ **Ravaoli F**, Dajti E, Simoni P, et al. Indocyanine green retention test predicts the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients «JOURNAL OF HEPATOLOGY», 2019, 70(1):e745
- ◆ Berger A, **Ravaoli F**, Farcau O, et al. How to use platelets and liver stiffness to rule out esophageal varices needing treatment? «JOURNAL OF HEPATOLOGY», 2019, 70(1):e634-e635
- ◆ Dajti E, **Ravaoli F**, Colecchia A, et al. The risk of hepatic decompensation is reduced, but not abolished after direct-acting antivirals: The role of portal hypertension «JOURNAL OF HEPATOLOGY», 2019, 70(1):e727
- ◆ Dajti E, **Ravaoli F**, Colecchia A, et al. The Risk Of Hepatic Decompensation Is Reduced, But Not Abolished After Direct-Acting Antivirals: The Role Of Spleen Stiffness Measurement «DIGESTIVE AND LIVER DISEASE», 2019, 51:e171-e172
- ◆ Marasco G, Ricci C, ..., **Ravaoli F**, ..., et al. Pancreatic Ultrasound Elastography And Its Clinical Use In Predicting The Risk Of Pancreatic Fistulas After Pancreatic Resection «DIGESTIVE AND LIVER DISEASE», 2019, 51:e165-e166
- ◆ Serra C, Dajti E, ... **Ravaoli F**, ... et al. Increased portal pressure is associated with elevated liver enzymes during pregnancy: the role of doppler-ultrasound and liver stiffness measurement «DIGESTIVE AND LIVER DISEASE», 2019, 51:e22-e23
- ◆ Azzaroli F, Simoni P, Arena R, Dajti E, **Ravaoli F**, et al. The role of bile acids profile and insulin resistance for the prediction of gallstone disease in a prospective cohort of blood donors «DIGESTIVE AND LIVER DISEASE», 2019, 51:e21
- ◆ **Ravaoli F**, Dajti E, Simoni P, et al. Indocyanine green retention test predicts the risk of portal hypertension-related events after direct-acting antiviral therapy in compensated advanced chronic liver disease patients «DIGESTIVE AND LIVER DISEASE», 2019, 51:e55+
- ◆ Dajti E, **Ravaoli F**, Colecchia A, Marasco G et al. The role of liver and spleen stiffness measurement in predicting hepatic decompensation after HCV eradication with direct antiviral agents therapy «DIGESTIVE AND LIVER DISEASE», 2019, 51:e64
- ◆ **Ravaoli F**, Colecchia, A.; Marasco, G.; Colli, A.; Dajti, E.; Di Biase, A.; Reggiani, M. L. B.; Berzigotti, A.; Pinzani, M.; Festi, D., A spleen stiffness measurement-based model for recognition of high-risk varices: Baveno VI criteria and beyond, «JOURNAL OF HEPATOLOGY», 2018, 68, pp. S75 - S76
- ◆ Colecchia, A.; **Ravaoli F**, Marasco, G.; Colli, A.; Dajti, E.; Di Biase, A.; Bacchi Reggiani, M. L.; Berzigotti, A.; Pinzani, M.; Festi, D., A spleen stiffness measurement-based model for the recognition of high-risk varices: Baveno VI criteria and beyond, «DIGESTIVE AND LIVER DISEASE», 2018, 50, pp. 33 - 34
- ◆ Simili, A.; Mazzella, G.; **Ravaoli F**, Davide, F.; Bacchi-Reggiani, M. L.; Porro, A.; Bazzoli, F.; Azzaroli, F., IL28 polymorphism and HCC after DAAs for chronic hepatitis C, «DIGESTIVE AND LIVER DISEASE», 2018, 50, pp. 32 - 33
- ◆ Simili, A.; Mazzella, G.; **Ravaoli F**, Festi, D.; Reggiani, M. L. Bacchi; Porro, A.; Bazzoli, F.; Azzaroli, F., P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C, «DIGESTIVE AND LIVER DISEASE», 2018, 50, pp. e218 - e219
- ◆ **Ravaoli F**, Colecchia, A.; Marasco, G.; Colli, A.; Dajti, E.; Alemanni, V. L.; Di Biase, A.; Reggiani, M. L. Bacchi; Berzigotti, A.; Pinzani, M.; Festi, D., PC.01.2 A SPLEEN STIFFNESS MEASUREMENT-BASED MODEL FOR THE RECOGNITION OF HIGH RISK VARICES: BAVENO VI CRITERIA AND BEYOND, «DIGESTIVE AND LIVER DISEASE», 2018, 50, pp. e63 - e64

- ◆ **Ravaoli, F.**; Dajti, E.; Colecchia, A.; Alemanni, V.; Marasco, G.; Tamè, M.; Azzaroli, F.; Brillanti, S.; Mazzella, G.; Festi, D., Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients, «JOURNAL OF HEPATOLOGY», 2018, 68, pp. S654 - S655
- ◆ **Ravaoli, F.**; Mazzella, G.; Andreone, P.; Conti, F.; Brillanti, S.; Buonfiglioli, F.; Serio, I.; Verucchi, G.; Reggiani, MLB; Marasco, G.; ,THU-492-Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients, Journal of Hepatology, 66, 1, S239-S240,2017
- ◆ Marasco, G; Colecchia, A; Colli, A; Casazza, G; **Ravaoli, F.**; Cucchetti, A; Cescon, M; Pinna, AD; Festi, D; ,THU-o86-The role of spleen stiffness measurement as predictor of hepatocellular carcinoma recurrence after curative resection in cirrhotic patients, Journal of Hepatology, 66,1,S213,2017, Elsevier
- ◆ **Ravaoli, F.**; Tamè, MR; Marasco, G; Vizioli, L; Morelli, MC; Pinna, AD; Conti, F; Andreone, P; Colecchia, A; Festi, D; ,THU-491-DAAs treatment in hepatitis C virus recurrence after Liver Transplantation: clinical usefulness of non-invasive methods, Journal of Hepatology, 66,1,S239,2017, Elsevier
- ◆ Kleinschmidt K, **Ravaoli F.**, Rondelli R, et al. The diagnostic role of liver stiffness measurement in predicting hepatic veno-occlusive disease (VOD) in pediatric hematopoietic stem cell transplantation (HSCT). Bone Marrow Transplant. 2017;52:S380
- ◆ **Ravaoli, F.**; Tamè, MR; Marasco, G; Vizioli, L; Morelli, MC; Pinna, AD; Conti, F; Andreone, P; Colecchia, A; Festi, D; ,DAAs treatment in HCV recurrence after liver transplantation: Clinical usefulness of non-invasive methods, Digestive and Liver Disease,49,1,e39,2017, Elsevier
- ◆ **Ravaoli, F.**; Marasco, G; Reggiani, ML Bacchi; Mazzella, G; Buonfiglioli, F; Porro, A; Brillanti, S; Colecchia, A; Festi, D; ,Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens, Digestive and Liver Disease,49,1,e40-e41,2017,Elsevier
- ◆ Salvatore, V; Mulazzani, L; Cantisani, V; Colecchia, A; Di Donato, R; Felicani, C; Ferrarini, A; Gamal, N; Grasso, V; Marasco, G; **Ravaoli F.**, et al. Liver stiffness fibrosis thresholds of Fibroscan® cannot be adopted by all new elastography machines: A comparative study, Digestive and Liver Disease, 49,1,e24,2017, Elsevier
- ◆ **Ravaoli, F.**; Mazzella, G; Andreone, P; Conti, F; Brillanti, S; Buonfiglioli, F; Serio, I; Verucchi, G; Reggiani, ML Bacchi; Marasco, G; ,Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients, Digestive and Liver Disease,49,1,e39,2017, Elsevier
- ◆ Marasco, G; Colecchia, A; Colli, A; Casazza, G; **Ravaoli, F.**; Cucchetti, A; Cescon, M; Pinna, AD; Festi, D; ,The role of Spleen Stiffness measurement as predictor of HCC recurrence after curative resection in cirrhotic patients, Digestive and Liver Disease,49,1,e41,2017, Elsevier
- ◆ A.R. Di Biase, G. Marasco, A. Colecchia, M.G. Berardi, F. **Ravaoli, F.** Iughetti, D. Festi. Clinical presentation of celiac disease and ESPGHAN Celiac Disease Guidelines retrospective real-time application in a Single- Center European Pediatric population: a 10 years experience. UEG Journal, Volume 4, Issue 5_suppl, October 2016
- ◆ **F. Ravaoli**, A. Colecchia, G. Marasco, K. Kleinschmidt, R. Masetti, A. Prete, A. Pession and D. Festi. Hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation (HSCT) in pediatric patients: role of liver stiffness.UEG Journal, Volume 4, Issue 5_suppl, October 2016

17/05/2024

Dott. Ravaoli Federico, 02/2024

